정신분열병 또는 정신분열형장애를 가진 입원환자에서 Risperidone과 Olanzapine의 효과의 비교 : 6주간의 개방적 전향적 연구 6 Weeks, Open-Labelled, Prospective Study = A Comparative Effectiveness Study of Risperidone and Olanzapine in the Treatment of Inpatient of Schizophrenia or Schizophreniform Disorder

다국어 초록 (Multilingual Abstract)

Objectives : Risperidone and olanzapine, which are atypical antipsychotics. are widely used in the treatment of schizophrenia as the 1st line drug, proving their effectiveness for both positive and negative symptoms. They also have many advantages even from the side effects. However, they show differences with the chemical structure and pharmacokinetics and they work differently to receptors. Researchers have studied the effect and side effect during the acute phase of schizophrenia as an open prospective study.
Methods : Forty subjects with DSM-IV schizophrenia or schizoaffective patients including 1) 1st onset schizophrenia patient, 2) patient who has been treated by the prior antipsychotics and not improved or even worse to be admitted again, were assigned to receive risperidone or olanzapine for 6 weeks. Psychopathology, adverse effect. weight change, fasting serum glucose, and drug cost were compared within and across groups.
Results : After 6 weeks later both treatment groups showed the significant decrease in PANSS positive, general psychopathology and total score while they did not show any significant difference between two groups. Risperidone group, however. showed the significant decrease in PANS negative score, which olanzapine group did not. In terms of adverse effect risperidone group showed more extrapyramidal symptom than olanzapine group. Body weight rised significantly after Gweeks, but no significant difference between two treatment groups. There were no significant indrease of fasting serum glucose level.
Conclusions : Risperidone and olanzapine are effective drugs which can be used during the acute phase of schizophrenia. Risperidone is expected to shorten the admission day and remission of the symptom of acute phase, mile olarizapine is more advantage in a neurologic side effect than rispendone.